Published in Z Parasitenkd on June 03, 1977
Suppression of cellular responses in mice during Trypanosoma cruzi infections. Infect Immun (1978) 1.18
Experimental Chagas' disease: kinetics of lymphocyte responses and immunological control of the transition from acute to chronic Trypanosoma cruzi infection. Infect Immun (1981) 1.17
On evasion of Trypanosoma cruzi from the host immune response. Lymphoproliferative responses to trypanosomal antigens during acute and chronic experimental Chagas' disease. Immunology (1981) 1.14
Delayed hypersensitivity to Trypanosoma cruzi in mice: specific suppressor cells in chronic infection. Immunology (1981) 1.03
Selective suppressive effects of Trypanosoma cruzi on activated human lymphocytes. Infect Immun (1989) 1.01
Contact sensitivity responses in mice infected with Trypanosoma cruzi. Infect Immun (1978) 0.99
Use of parasite antigens and interleukin-2 to enhance suppressed immune responses during Trypanosoma cruzi infection in mice. Infect Immun (1987) 0.92
Trypanosoma cruzi-induced immunosuppression: selective triggering of CD4+ T-cell death by the T-cell receptor-CD3 pathway and not by the CD69 or Ly-6 activation pathway. Infect Immun (1996) 0.89
Trypanosoma cruzi-induced suppression of human peripheral blood lymphocytes activated via the alternative (CD2) pathway. Infect Immun (1990) 0.85
Trypanosoma cruzi induces suppression of DNA synthesis and inhibits expression of interleukin-2 receptors by stimulated human B lymphocytes. Immunology (1991) 0.83
Interactions between murine macrophages and obligate intracellular protozoa. Am J Pathol (1981) 0.83
Suppression of antibody responses in humans infected with Trypanosoma cruzi. Infect Immun (1980) 0.82
Immunization of mice with Trypanosoma cruzi polyribosomes. Infect Immun (1980) 0.82
Trypanosoma cruzi trans-sialidase prevents elicitation of Th1 cell response via interleukin 10 and downregulates Th1 effector cells. Infect Immun (2015) 0.78
The immunosuppressive and mitogenic effects of Trypanosoma musculi. Clin Exp Immunol (1978) 0.78
Mitomycin C-treated Trypanosoma cruzi in vaccination of mice: induction of immunosuppression but not protection. Infect Immun (1981) 0.75
Dysfunction in the neural circuitry of emotion regulation--a possible prelude to violence. Science (2000) 4.86
Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science (1992) 3.71
Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. Clin Microbiol Rev (1998) 3.59
Rapid accurate field diagnosis of Indian visceral leishmaniasis. Lancet (1998) 3.55
Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J Clin Invest (1985) 3.41
Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis. Proc Natl Acad Sci U S A (1993) 3.40
Interleukin 10 and interferon gamma regulation of experimental Trypanosoma cruzi infection. J Exp Med (1992) 3.34
Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest (1993) 3.28
rK39: a cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis. J Infect Dis (1996) 2.93
New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis (1986) 2.92
Newly recognized fatal protozoan disease of dogs. J Am Vet Med Assoc (1988) 2.89
Suppression and enhancement of emotional responses to unpleasant pictures. Psychophysiology (2000) 2.73
Regulation of Trypanosoma cruzi infections in vitro and in vivo by transforming growth factor beta (TGF-beta). J Exp Med (1991) 2.68
Diagnostic and prognostic value of K39 recombinant antigen in Indian leishmaniasis. J Parasitol (1995) 2.37
Anterior cingulate activity as a predictor of degree of treatment response in major depression: evidence from brain electrical tomography analysis. Am J Psychiatry (2001) 2.31
Recombinant interleukin 7, pre-B cell growth factor, has costimulatory activity on purified mature T cells. J Exp Med (1989) 2.30
Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. J Immunol (1994) 2.25
CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity (1996) 2.11
Characterization of human CD8+ T cells reactive with Mycobacterium tuberculosis-infected antigen-presenting cells. J Exp Med (1998) 2.06
Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res (2000) 1.98
Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family. Infect Immun (1999) 1.95
Selection of a skin test antigen for American visceral leishmaniasis. Am J Trop Med Hyg (1986) 1.93
Regulation of Trypanosoma cruzi infection in mice by gamma interferon and interleukin 10: role of NK cells. Infect Immun (1996) 1.93
rK39 enzyme-linked immunosorbent assay for diagnosis of Leishmania donovani infection. Clin Diagn Lab Immunol (1998) 1.90
Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis braziliensis. J Infect Dis (1987) 1.87
P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol (2001) 1.86
Murine thymocytes proliferate in direct response to interleukin-7. Blood (1989) 1.86
Functional but not structural subgenual prefrontal cortex abnormalities in melancholia. Mol Psychiatry (2004) 1.83
A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12. J Exp Med (1995) 1.81
T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection. J Immunol (2000) 1.76
Transforming growth factor beta as a virulence mechanism for Leishmania braziliensis. Proc Natl Acad Sci U S A (1993) 1.76
Metabolic rate in the right amygdala predicts negative affect in depressed patients. Neuroreport (1998) 1.76
Duration of immunity to tuberculosis in mice vaccinated intravenously with oil-treated cell walls of Mycobacterium bovis strain BCG. J Immunol (1967) 1.75
Factors influencing protection against experimental tuberculosis in mice by heat-stable cell wall vaccines. J Bacteriol (1966) 1.75
IL-12 enhances Th1-type responses in human Leishmania donovani infections. J Immunol (1995) 1.69
Transcriptional complementarity in breast cancer: application to detection of circulating tumor cells. Mol Diagn (2001) 1.67
Molecular and immunological characterization of Mycobacterium tuberculosis CFP-10, an immunodiagnostic antigen missing in Mycobacterium bovis BCG. J Clin Microbiol (2000) 1.66
Immunopathology of experimental cutaneous leishmaniasis. Am J Pathol (1984) 1.65
Infection-immunity in tularemia: specificity of cellular immunity. Infect Immun (1972) 1.62
Expression cloning of an immunodominant family of Mycobacterium tuberculosis antigens using human CD4(+) T cells. J Exp Med (2000) 1.60
Oocyst-induced murine toxoplasmosis: life cycle, pathogenicity, and stage conversion in mice fed Toxoplasma gondii oocysts. J Parasitol (1997) 1.59
Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis. Infect Immun (1999) 1.55
Successful use of a defined antigen/GM-CSF adjuvant vaccine to treat mucosal Leishmaniasis refractory to antimony: A case report. Braz J Infect Dis (2001) 1.54
Classically restricted human CD8+ T lymphocytes derived from Mycobacterium tuberculosis-infected cells: definition of antigenic specificity. J Immunol (2001) 1.54
Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect Immun (1998) 1.53
Absence of the tight junctional protein AF-6 disrupts epithelial cell-cell junctions and cell polarity during mouse development. Curr Biol (1999) 1.52
Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect Immun (2001) 1.51
Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis. Laryngoscope (2000) 1.51
Regulation of T cell proliferation by IL-7. J Immunol (1990) 1.50
IL-10 is induced during HIV-1 infection and is capable of decreasing viral replication in human macrophages. J Immunol (1994) 1.46
Suppressed antibody responses to sheep erythrocytes in mice with chronic Trypanosoma cruzi infections are restored with interleukin 2. J Immunol (1984) 1.45
Mass spectrometric identification of mtb81, a novel serological marker for tuberculosis. J Clin Microbiol (2000) 1.44
A cloned antigen (recombinant K39) of Leishmania chagasi diagnostic for visceral leishmaniasis in human immunodeficiency virus type 1 patients and a prognostic indicator for monitoring patients undergoing drug therapy. J Infect Dis (1998) 1.43
Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am J Trop Med Hyg (1997) 1.43
Factors influencing excystation in Cryptosporidium oocysts from cattle. J Parasitol (1985) 1.42
Molecular cloning and immunologic reactivity of a novel low molecular mass antigen of Mycobacterium tuberculosis. J Immunol (1998) 1.38
Cloning, characterization and serological evaluation of K9 and K26: two related hydrophilic antigens of Leishmania chagasi. Mol Biochem Parasitol (1999) 1.38
Quantitative in vitro drug potency and drug susceptibility evaluation of Leishmania ssp. from patients unresponsive to pentavalent antimony therapy. Am J Trop Med Hyg (1990) 1.37
Cloning and expression of Trypanosoma cruzi ribosomal protein P0 and epitope analysis of anti-P0 autoantibodies in Chagas' disease patients. J Exp Med (1992) 1.37
Heterologous antibody responses in mice with chronic T. cruzi infection: depressed T helper function restored with supernatants containing interleukin 2. J Immunol (1984) 1.35
Identification and synthesis of a major conserved antigenic epitope of Trypanosoma cruzi. Proc Natl Acad Sci U S A (1992) 1.34
Immunofluorescent antibody test in American visceral leishmaniasis: sensitivity and specificity of different morphological forms of two Leishmania species. Am J Trop Med Hyg (1983) 1.32
Identification of specific and cross-reactive antigens of Leishmania donovani chagasi by human infection sera. J Immunol (1987) 1.32
LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J Immunol (1998) 1.31
Mycobacterium tuberculosis-reactive CD8+ T lymphocytes: the relative contribution of classical versus nonclassical HLA restriction. J Immunol (2000) 1.31
Molecular cloning, expression, and immunogenicity of MTB12, a novel low-molecular-weight antigen secreted by Mycobacterium tuberculosis. Infect Immun (1998) 1.28
Serodiagnosis of Asian leishmaniasis with a recombinant antigen from the repetitive domain of a Leishmania kinesin. Trans R Soc Trop Med Hyg (1995) 1.27
Thalamic metabolic rate predicts EEG alpha power in healthy control subjects but not in depressed patients. Biol Psychiatry (1999) 1.25
A multi-epitope synthetic peptide and recombinant protein for the detection of antibodies to Trypanosoma cruzi in radioimmunoprecipitation-confirmed and consensus-positive sera. J Infect Dis (1999) 1.25
Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Infect Immun (2002) 1.25
A role for host phosphoinositide 3-kinase and cytoskeletal remodeling during Cryptosporidium parvum infection. Infect Immun (1999) 1.24
Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. J Immunol (1996) 1.24
Evaluation of the micro enzyme-linked immunosorbent assay (ELISA) for antibodies in American visceral leishmaniasis: antigen selection for detection of infection-specific responses. Am J Trop Med Hyg (1986) 1.24
Effect of treatment with BCG on the course of visceral leishmaniasis in BALB/c mice. Infect Immun (1977) 1.23
A review of Sarcocystis neurona and equine protozoal myeloencephalitis (EPM). Vet Parasitol (2001) 1.21
Lymphokine-induced inhibition of growth of Eimeria bovis and Eimeria papillata (Apicomplexa) in cultured bovine monocytes. Infect Immun (1985) 1.21
Immune responses of leishmaniasis patients to heat shock proteins of Leishmania species and humans. Infect Immun (1995) 1.20
Human purified protein derivative-specific CD4+ T cells use both CD95-dependent and CD95-independent cytolytic mechanisms. J Immunol (1998) 1.19
Spleen cell-mediated suppression of IgG production to a non-parasite antigen during chronic Trypanosoma cruzi infection in mice. J Immunol (1983) 1.18
Molecular karyotype of species and subspecies of Leishmania. Mol Biochem Parasitol (1986) 1.17
Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis. J Immunol (2001) 1.16
Serological expression cloning and immunological evaluation of MTB48, a novel Mycobacterium tuberculosis antigen. J Clin Microbiol (2001) 1.15
A highly sensitive and subspecies-specific surface antigen enzyme- linked immunosorbent assay for diagnosis of Johne's disease. Clin Vaccine Immunol (2006) 1.15
Antibody responses of visceral leishmaniasis patients to gp63, a major surface glycoprotein of Leishmania species. J Infect Dis (1993) 1.15
Cytotoxicity in human mucosal and cutaneous leishmaniasis. Parasite Immunol (1995) 1.15
Identification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis. Oncogene (2000) 1.14
Antigenic cross-reactivity between Mycobacterium bovis (BCG) and Leishmania donovani. Infect Immun (1977) 1.14
Identification and characterization of prostein, a novel prostate-specific protein. Cancer Res (2001) 1.12
Human T cell responses to gp63, a surface antigen of Leishmania. J Immunol (1991) 1.12
Leishmania gp63 molecule implicated in cellular adhesion lacks an Arg-Gly-Asp sequence. Mol Biochem Parasitol (1990) 1.10
Serodiagnosis of human granulocytic ehrlichiosis by using novel combinations of immunoreactive recombinant proteins. J Clin Microbiol (2001) 1.10
Ribosomes of acid-fast bacilli: immunogenicity, serology, and in vitro correlates of delayed hypersensitivity. Infect Immun (1973) 1.10
Experimental Sarcocystis hominis infection in cattle: lesions and ultrastructure of sarcocysts. J Parasitol (1988) 1.10
Redescription of Neospora caninum and its differentiation from related coccidia. Int J Parasitol (2002) 1.10
Soluble IL-2 receptor as an agent of serum-mediated suppression in human visceral leishmaniasis. J Immunol (1991) 1.09
Dietary composition and physiologic adaptations to energy restriction. Am J Clin Nutr (2000) 1.09
Characterization of a membrane antigen of Leishmania amazonensis that stimulates human immune responses. J Immunol (1991) 1.09
Enzyme-linked immunosorbent assay for serological diagnosis of Chagas' disease employing a Trypanosoma cruzi recombinant antigen that consists of four different peptides. J Clin Microbiol (2001) 1.09
Sarcocystis neurona n. sp. (Protozoa: Apicomplexa), the etiologic agent of equine protozoal myeloencephalitis. J Parasitol (1991) 1.09
Serodiagnosis of Chagas' disease by enzyme-linked immunosorbent assay using two synthetic peptides as antigens. J Clin Microbiol (1994) 1.08